Table 2.
Distribution of Occurrence of New ECG Abnormalities During EDIC Follow‐up by Baseline Characteristics
| Baseline Characteristics | New Major ECG Abnormality, N (%) | Any New ECG Abnormality, N (%) |
|---|---|---|
| All (n=1314) | 172 (13.1) | 1016 (77.3) |
| Age group, yr | ||
| <40 (n=931) | 103 (11.1) | 701 (75.3) |
| ≥40 (n=383) | 69 (18.0)a | 315 (82.3)a |
| Gender | ||
| Female (n=624) | 78 (12.5) | 481 (77.1) |
| Male (n=690) | 94 (13.6) | 535 (77.5) |
| Study cohortb | ||
| Primary (n=653) | 93 (14.2) | 506 (77.5) |
| Secondary (n=661) | 79 (12.0) | 510 (77.2) |
| DCCT treatment groupc | ||
| Intensive (n=656) | 83 (12.7) | 499 (76.1) |
| Conventional (n=658) | 89 (13.5) | 517 (78.6) |
| HbA1c | ||
| <8.0% (n=670) | 70 (10.5) | 505 (75.4) |
| ≥8.0% (n=644) | 102 (15.8)a | 511 (79.4) |
DCCT indicates Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications study; HbA1c, glycosylated hemoglobin.
Significant differences; P<0.05.
Primary prevention cohort includes DCCT participants with diabetes duration 1 to 5 years, no retinopathy, and urinary albumin excretion rate <40 mg/day. Secondary intervention cohort includes DCCT participants 1 to 15 years duration, very mild‐to‐moderate nonproliferative retinopathy, and albumin excretion rate <200 mg/day.
Intensive therapy aimed to achieve levels of glycemia as close to the nondiabetic range as safely possible, whereas conventional therapy aimed to maintain clinical well‐being with no specific glucose targets.